According to Roots Analysis, thepharmaceutical vials market is expected to increase from USD 11.03 billion in 2024 to USD 15.85 billion in 2030, with a 6% CAGR over the forecast period until 2030.

Key Takeaways:

A detailed assessment of the current market landscape of pharmaceutical vials.

A competitive analysis of pharmaceutical vial manufacturers, segmented into four categories, namely small, mid-sized companies, and large and very large companies.

Elaborate profiles of prominent players engaged in the development of pharmaceutical vials, based in North America, Europe and Asia Pacific (shortlisted on the basis of the number of pipeline products).

An analysis of the partnerships that have been inked by stakeholders engaged in this domain, during the period 2015-2021 (till September).

An elaborate discussion on the key trends that are likely to have an impact on the future adoption of innovative primary packaging systems.

An in-depth analysis to estimate the current and future demand for pharmaceutical vials based on various relevant parameters, for the period 2021-2030.

A case study on the use of robotic machinery in pharmaceutical manufacturing and fill / finish operations, highlighting the advantages of using automation / automated technologies in such processes.

A case study on pre-sterilized / RTU pharmaceutical vials that are available nowadays.

A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)

Type of Fabrication Material Used

Glass

Plastic

Sterilization Status

Pre-sterilized

Unsterilized

Key Geographical Region

North America

Europe

Asia Pacific

Latin America

Middle East and North Africa

Rest of the World

Key companies covered in the report

Chongqing Zhengchuan Pharmaceutical Packaging

Corning

DANYANG XIANGHE PHARMACEUTICAL PACKAGING

DWK Life Sciences

Gerresheimer

Ningbo Zhengli Pharmaceutical Packaging

Nipro

Origin Pharma Packaging

Pacific Vial Manufacturing

SCHOTT

SGD Pharma

Shandong Pharmaceutical Glass

Stevanato Group

Thermo Fisher Scientific

Worldwide Glass Resources

For more information please click on the following link:

https://www.rootsanalysis.com/reports/global-pharmaceutical-vials-market.html

About Roots Analysis

Roots Analysis is a global leader in the market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. All reports provided by us are structured in a way that enables the reader to develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we provide bespoke research / consulting services dedicated to serve our clients in the best possible way.

Contact US

Gaurav Chaudhary

+1 (857) 387 7999
+44 (748) 188 1310

Email: sales@rootsanalysis.com

The overall success of biologics has resulted in a growing demand from patients, insurers and government bodies across the world. Owing to their therapeutic potential and target specificity, we anticipate the demand for such drug products to persist over the coming years.

According to Roots Analysis, the biologics contract manufacturing market size was valued at USD 22.2 billion in 2024 and likely to hit over USD 58 billion by 2035, growing at a CAGR of 9.12 during the forecast period 2023 to 2035

The biopharmaceutical contract manufacturing market is highly competitive, and in such a fragmented (competitive) market, possession of advanced capabilities and specialized expertise serves as an important differentiating factor.

Thus, in order to meet the growing requirements of their clients and to improve their capabilities, several contract manufacturers have entered into partnerships with each other. This allows CMOs to offer a wide range of services to their clients and helps to maintain a long-term relationship with them, which are some of the key drivers anticipated to boost the market growth.

By type of service offered, API manufacturing segment is expected to account for the largest share of the global biologics contract manufacturing market

The large share of this market is mainly attributed to the significant capital investments, including facility cost, material cost and other ancillary expenses are associated with the manufacturing of biologics, considering this stakeholders rely on the expertise of CMOs for API production.

By type of biology manufactured, antibodies hold a significant market share during the forecast period

The demand for antibodies in the biologics contract manufacturing market is increasing globally due to their ability to target a broad range of target antigens, for instance cancer cells, immunosuppressor and immunomodulatory molecules.

Additionally, more than 100 antibodies have been approved across the globe and an increasing number of clinical trials related to antibodies are also underway. Furthermore, the increasing prevalence of cancer is projected to increase the demand for monoclonal antibodies as they aid in the treatment of cancer.

Biologics Contract Manufacturing Market Regional Analysis

North America and Europe are currently dominating the biologics contract manufacturing market. This can be attributed to the fact that the number of manufacturing facilities in these regions is relatively higher.

Additionally, the market in Asia-Pacific is expected to grow at a CAGR of 11.4%, as the manufacturers based in the region are continuously expanding their capabilities / capacities over the last few years, specifically post the COVID-19 pandemic. Based on the aforementioned reasons, we are led to believe that the general / expected trend will evolve over the coming years, with Asia-Pacific capturing a slightly higher market share than North America and Europe.

Key Market Players

AcuraBio, AGC Biologics, Boehringer Ingelheim, Catalent, Cell Therapies, Celltrion, Cytiva, Charles River Laboratories, FUJIFILM Diosynth Biotechnologies, KBI Biopharma, Kemwell Biopharma, Lonza, Miltenyi Biotec, Minaris Regenerative Medicine, Novasep, Olon, Patheon, Piramal Pharma Solutions, Samsung Biologics, Sandoz, Takara Bio, Vetter Pharma, Wuxi Biologics.

Biologics Contract Manufacturing Market Key Segments

by Type of Service Offered

API Manufacturing

FDF Manufacturing

by Type of Biologic Manufactured

Antibodies

Cell Therapies

Vaccines

Other Biologics

by Type of Expression System Used

Mammalian Expression Systems

Microbial Expression Systems

Other Expression Systems

by Scale of Operation

Preclinical / Clinical

Commercial

by Company Size

Small

Mid-sized

Large and Very Large

by Key Geographical Regions

North America

Europe

Asia-Pacific

Latin America

Middle East and North Africa

by Leading Players

BioXcellence

Catalent Biologics

FUJIFILM Diosynth Biotechnologies

Lonza

Samsung BioLogics

WuXi Biologics

About Roots Analysis

Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. All reports provided by us are structured in a way that enables the reader to develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we provide bespoke research / consulting services dedicated to serve our clients in the best possible way.

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

+44 (122) 391 1091

Email: sales@rootsanalysis.com